Brooklyn ImmunoTherapeutics (BTX) Stock Enters New Round of Rally

In recent times, the Brooklyn ImmunoTherapeutics (NYSE: BTX ) stock has emerged as one of the major gainers in the biotech sector and the trend continued on Tuesday.

Brooklyn ImmunoTherapeutics (BTX) Stock Enters New Round of Rally

Yesterday, the stock soared by as high as 27% to take its gains for the past month to 160%. In light of such considerable gains, it might be a good idea for investors to consider taking a much closer look at Brooklyn ImmunoTherapeutics. Earlier this month, the company had announced the appointment of Howard J. Federoff as the President and Chief Executive Officer.

Related:  Under $5 Alpine Immune Sciences' Stock (NASDAQ: ALPN) Soars to Surpass $10 Line

He took charge from April 16. The announcement had been made on April 6 and soon after the stock surged by 79% Hence, it was a clear indication of the excitement in the market with regards to the appointment of Federoff. Ronald Guido had been serving as the interim CEO prior to the appointment of Federoff. Moreover, the stock is up another 55 in the pre-market session today.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life